Summary:
Midwest Research Group is conducting a 12 week, Randomized, Double blind, Parallel group, Placebo-controlled, Flexibly dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults with Moderate to Severe Binge Eating Disorder
Qualified Participants Must:
• Be between 18 and 55 years of age, inclusive, at time of informed consent
•
Be BED diagnosis including on average binge episodes 2 days a week for at least 6 months prior to screening
•
Have BED that is at least at moderate severity with at least 3 binge eating days for each of the 2 weeks prior to first dose of study drug as documented in the your binge diary
•
Have a body weight index (BMI) between 18 and 45 kg/m2
Qualified Participants May Receive:
Study Medication, Psychiatric Evaluation, Medical Evaluation, and Compensation.